Advertisement


Jaafar Bennouna, MD, on Colorectal Cancer: Clinical Trial Findings on Targeted Treatments and Chemotherapy

2017 ESMO Congress

Advertisement

Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (Abstract 477O).



Related Videos

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Kidney Cancer

Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers

Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.

Gynecologic Cancers

Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial

Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (Abstract 929O).

Gynecologic Cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.

Advertisement

Advertisement




Advertisement